Rationale and design of the DIGIT‐HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double‐blind, placebo‐controlled study

AIMS: Despite recent advances in the treatment of chronic heart failure (HF), mortality and hospitalizations still remain high. Additional therapies to improve mortality and morbidity are urgently needed. The efficacy of cardiac glycosides – although regularly used for HF treatment – remains unclear...

Descripción completa

Detalles Bibliográficos
Autores principales: Bavendiek, Udo, Berliner, Dominik, Dávila, Lukas Aguirre, Schwab, Johannes, Maier, Lars, Philipp, Sebastian A., Rieth, Andreas, Westenfeld, Ralf, Piorkowski, Christopher, Weber, Kristina, Hänselmann, Anja, Oldhafer, Maximiliane, Schallhorn, Sven, von der Leyen, Heiko, Schröder, Christoph, Veltmann, Christian, Störk, Stefan, Böhm, Michael, Koch, Armin, Bauersachs, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607489/
https://www.ncbi.nlm.nih.gov/pubmed/30892806
http://dx.doi.org/10.1002/ejhf.1452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607489/
https://www.ncbi.nlm.nih.gov/pubmed/30892806
http://dx.doi.org/10.1002/ejhf.1452

Ejemplares similares